toripalimab,gemcitabine,cisplatin
Shanghai Junshi Bioscience,Coherus
['jupiter-02', 'coherus']
final analysis of the jupiter-02 clinical trial will be presented today at 4:30pm cdt at the annual meeting. excited to see what kind of impact these results may have on potentially improving the lives of patients with #npc. #asco23 
Leader in developing and commercializing high-quality, high-value biosimilar therapeutics.